Hapoalim Securities Initiates Coverage on Genzyme (GENZ) with a Hold; Pipeline Promising, But Near-Term Competition
Tweet Send to a Friend
Hapoalim Securities initiates coverage on Genzyme (Nasdaq: GENZ) with a Hold. Price target $55.
Hapoalim analyst says, "Genzyme's franchise drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Hapoalim analyst says, "Genzyme's franchise drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
